Apolipoprotein A-IV concentrations and cancer in a large cohort of chronic kidney disease patients: results from the GCKD study.
Apolipoprotein A-IV
Cancer
Inflammation
Kidney function
Prospective study
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
07 Mar 2024
07 Mar 2024
Historique:
received:
24
03
2023
accepted:
26
02
2024
medline:
11
3
2024
pubmed:
8
3
2024
entrez:
8
3
2024
Statut:
epublish
Résumé
Chronic kidney disease (CKD) is highly connected to inflammation and oxidative stress. Both favour the development of cancer in CKD patients. Serum apolipoprotein A-IV (apoA-IV) concentrations are influenced by kidney function and are an early marker of kidney impairment. Besides others, it has antioxidant and anti-inflammatory properties. Proteomic studies and small case-control studies identified low apoA-IV as a biomarker for various forms of cancer; however, prospective studies are lacking. We therefore investigated whether serum apoA-IV is associated with cancer in the German Chronic Kidney Disease (GCKD) study. These analyses include 5039 Caucasian patients from the prospective GCKD cohort study followed for 6.5 years. Main inclusion criteria were an eGFR of 30-60 mL/min/1.73m Mean apoA-IV concentrations of the entire cohort were 28.9 ± 9.8 mg/dL (median 27.6 mg/dL). 615 patients had a history of cancer before the enrolment into the study. ApoA-IV concentrations above the median were associated with a lower odds for a history of cancer (OR = 0.79, p = 0.02 when adjusted age, sex, smoking, diabetes, BMI, albuminuria, statin intake, and eGFR Our data indicate an association of high apoA-IV concentrations with reduced frequencies of a history of cancer as well as incident fatal and non-fatal cancer events in a large cohort of patients with CKD.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic kidney disease (CKD) is highly connected to inflammation and oxidative stress. Both favour the development of cancer in CKD patients. Serum apolipoprotein A-IV (apoA-IV) concentrations are influenced by kidney function and are an early marker of kidney impairment. Besides others, it has antioxidant and anti-inflammatory properties. Proteomic studies and small case-control studies identified low apoA-IV as a biomarker for various forms of cancer; however, prospective studies are lacking. We therefore investigated whether serum apoA-IV is associated with cancer in the German Chronic Kidney Disease (GCKD) study.
METHODS
METHODS
These analyses include 5039 Caucasian patients from the prospective GCKD cohort study followed for 6.5 years. Main inclusion criteria were an eGFR of 30-60 mL/min/1.73m
RESULTS
RESULTS
Mean apoA-IV concentrations of the entire cohort were 28.9 ± 9.8 mg/dL (median 27.6 mg/dL). 615 patients had a history of cancer before the enrolment into the study. ApoA-IV concentrations above the median were associated with a lower odds for a history of cancer (OR = 0.79, p = 0.02 when adjusted age, sex, smoking, diabetes, BMI, albuminuria, statin intake, and eGFR
CONCLUSIONS
CONCLUSIONS
Our data indicate an association of high apoA-IV concentrations with reduced frequencies of a history of cancer as well as incident fatal and non-fatal cancer events in a large cohort of patients with CKD.
Identifiants
pubmed: 38454416
doi: 10.1186/s12885-024-12053-8
pii: 10.1186/s12885-024-12053-8
pmc: PMC10921727
doi:
Substances chimiques
apolipoprotein A-IV
0
Apolipoproteins A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
320Subventions
Organisme : German Ministry of Education and Research
ID : FKZ 01ER 0804, 01ER 0818, 01ER 0819, 01ER 0820, and 01ER 0821
Organisme : Austrian Science Fund
ID : W-1253 DK HOROS
Investigateurs
Markus P Schneider
(MP)
Mario Schiffer
(M)
Hans-Ulrich Prokosch
(HU)
Barbara Bärthlein
(B)
Andreas Beck
(A)
André Reis
(A)
Arif B Ekici
(AB)
Susanne Becker
(S)
Ulrike Alberth-Schmidt
(U)
Anke Weigel
(A)
Sabine Marschall
(S)
Eugenia Schefler
(E)
Gerd Walz
(G)
Anna Köttgen
(A)
Ulla T Schultheiß
(UT)
Simone Meder
(S)
Erna Mitsch
(E)
Ursula Reinhard
(U)
Jürgen Floege
(J)
Turgay Saritas
(T)
Alice Gross
(A)
Elke Schaeffner
(E)
Seema Baid-Agrawal
(S)
Kerstin Theisen
(K)
Hermann Haller
(H)
Martin Zeier
(M)
Claudia Sommerer
(C)
Mehtap Aykac
(M)
Gunter Wolf
(G)
Martin Busch
(M)
Andy Steiner
(A)
Thomas Sitter
(T)
Vera Krane
(V)
Antje Börner-Klein
(A)
Britta Bauer
(B)
Peter Oefner
(P)
Wolfram Gronwald
(W)
Matthias Schmid
(M)
Jennifer Nadal
(J)
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2024. The Author(s).
Références
Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786–802.
pubmed: 34175022
doi: 10.1016/S0140-6736(21)00519-5
Malyszko J, Tesarova P, Capasso G, Capasso A. The link between kidney disease and cancer: complications and treatment. Lancet. 2020;396(10246):277–87.
pubmed: 32711803
doi: 10.1016/S0140-6736(20)30540-7
Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–52.
pubmed: 27887750
doi: 10.1016/S0140-6736(16)32064-5
Lees JS, Ho F, Parra-Soto S, Celis-Morales C, Welsh P, Sullivan MK, Jani BD, Sattar N, Lang NN, Pell JP, et al. Kidney function and cancer risk: an analysis using creatinine and cystatin C in a cohort study. EClinicalMedicine. 2021;38:101030.
pubmed: 34505030
pmcid: 8413238
doi: 10.1016/j.eclinm.2021.101030
Jankowski J, Floege J, Fliser D, Bohm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–72.
pubmed: 33720773
pmcid: 7969169
doi: 10.1161/CIRCULATIONAHA.120.050686
Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584–96.
pubmed: 26122183
doi: 10.1038/nrclinonc.2015.105
Amiri FS. Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers. Ren Fail. 2016;38(4):530–44.
pubmed: 26907957
doi: 10.3109/0886022X.2016.1148523
Utermann G, Beisiegel U. Apolipoprotein A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. Isolation and quantification. Eur J Biochem. 1979;99:333–43.
pubmed: 115688
doi: 10.1111/j.1432-1033.1979.tb13261.x
Green PHR, Glickman RM, Riley JW, Qinet E. Human apolipoprotein A-IV. Intestinal origin and distribution in plasma. J Clin Invest. 1980;65:911–9.
pubmed: 6987270
pmcid: 434480
doi: 10.1172/JCI109745
Wang F, Kohan AB, Lo CM, Liu M, Howles P, Tso P. Apolipoprotein A-IV: a protein intimately involved in metabolism. J Lipid Res. 2015;56:1403–18.
pubmed: 25640749
pmcid: 4513983
doi: 10.1194/jlr.R052753
Ezeh B, Haiman M, Alber HF, Kunz B, Paulweber B, Kraft HG, Weidinger F, Pachinger O, Dieplinger H, Kronenberg F. Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. J Lipid Res. 2003;44:1523–9.
pubmed: 12777472
doi: 10.1194/jlr.M300060-JLR200
Stein O, Stein Y, Lefevre M, Roheim PS. The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from another analog of phosphatidylcholine. Biochim Biophys Acta. 1986;878:7–13.
pubmed: 3089295
doi: 10.1016/0005-2760(86)90337-1
Kronenberg F. Apolipoprotein L1 and apolipoprotein A-IV and their association with kidney function. Curr Opin Lipidol. 2017;28:39–45.
pubmed: 27870653
doi: 10.1097/MOL.0000000000000371
Vowinkel T, Mori M, Krieglstein CF, Russell J, Saijo F, Bharwani S, Turnage RH, Davidson WS, Tso P, Granger DN, et al. Apolipoprotein A-IV inhibits experimental colitis. J Clin Invest. 2004;114:260–9.
pubmed: 15254593
pmcid: 450164
doi: 10.1172/JCI200421233
Recalde D, Ostos MA, Badell E, Garcia-Otin AL, Pidoux J, Castro G, Zakin MM, Scott-Algara D. Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide. Arterioscler Thromb Vasc Biol. 2004;24(4):756–61.
pubmed: 14751811
doi: 10.1161/01.ATV.0000119353.03690.22
Xu XR, Wang Y, Adili R, Ju L, Spring CM, Jin JW, Yang H, Neves MAD, Chen P, Yang Y, et al. Apolipoprotein A-IV binds alphaIIbbeta3 integrin and inhibits thrombosis. Nat Commun. 2018;9:3608.
pubmed: 30190457
pmcid: 6127106
doi: 10.1038/s41467-018-05806-0
Haiman M, Salvenmoser W, Scheiber K, Lingenhel A, Rudolph C, Schmitz G, Kronenberg F, Dieplinger H. Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. Kidney Int. 2005;68:1130–6.
pubmed: 16105043
doi: 10.1111/j.1523-1755.2005.00519.x
Stangl S, Kollerits B, Lamina C, Meisinger C, Huth C, Stoeckl A, Daehnhardt D, Boeger CA, Kraemer BK, Peters A, et al. Association between apolipoprotein A-IV concentrations and chronic kidney disease in two large population-based cohorts: results from the KORA studies. J Intern Med. 2015;278(4):410–23.
pubmed: 26037138
doi: 10.1111/joim.12380
Boes E, Fliser D, Ritz E, König P, Lhotta K, Mann JFE, Müller GA, Neyer U, Riegel W, Riegler P, et al. Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2006;17:528–36.
pubmed: 16382017
doi: 10.1681/ASN.2005070733
Kronenberg F, Stühlinger M, Trenkwalder E, Geethanjali FS, Pachinger O, Von Eckardstein A, Dieplinger H. Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol. 2000;36:751–7.
pubmed: 10987595
doi: 10.1016/S0735-1097(00)00775-0
Li J, Song M, Qian D, Lu W, Wang J, Jiang G, Jin J, Wu X, Huang L. Decreased plasma apolipoprotein A-IV levels in patients with acute coronary syndrome. Clin Invest Med. 2013;36:E207–15.
pubmed: 23906492
doi: 10.25011/cim.v36i4.19954
Kollerits B, Krane V, Drechsler C, Lamina C, Maerz W, Ritz E, Wanner C, Kronenberg F. Apolipoprotein A-IV concentrations and clinical outcomes in haemodialysis patients with type 2 diabetes mellitus - a post hoc analysis of the 4D Study. J Intern Med. 2012;272(6):592–600.
pubmed: 22891946
doi: 10.1111/j.1365-2796.2012.02585.x
Schwaiger JP, Kollerits B, Steinbrenner I, Weissensteiner H, Schonherr S, Forer L, Kotsis F, Lamina C, Schneider MP, Schultheiss UT, et al. Apolipoprotein A-IV concentrations and clinical outcomes in a large chronic kidney disease cohort: results from the GCKD study. J Intern Med. 2022;291(5):622–36.
pubmed: 34914850
pmcid: 9305919
doi: 10.1111/joim.13437
Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H, Stieber P. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:1127–33.
pubmed: 19336561
doi: 10.1158/1055-9965.EPI-08-0653
Lorkova L, Pospisilova J, Lacheta J, Leahomschi S, Zivny J, Cibula D, Zivny J, Petrak J. Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: a potential biomarker identified by proteomics. Oncol Rep. 2012;27(2):318–24.
pubmed: 22020625
Timms JF, Arslan-Low E, Kabir M, Worthington J, Camuzeaux S, Sinclair J, Szaub J, Afrough B, Podust VN, Fourkala EO, et al. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. Proteomics Clin Appl. 2014;8:982–93.
pubmed: 25290619
pmcid: 4737403
doi: 10.1002/prca.201400063
Bharali D, Banerjee BD, Bharadwaj M, Husain SA, Kar P. Expression analysis of apolipoproteins AI & AIV in hepatocellular carcinoma: a protein-based hepatocellular carcinoma-associated study. Indian J Med Res. 2018;147(4):361–8.
pubmed: 29998871
pmcid: 6057253
doi: 10.4103/ijmr.IJMR_1358_16
Abulaizi M, Tomonaga T, Satoh M, Sogawa K, Matsushita K, Kodera Y, Obul J, Takano S, Yoshitomi H, Miyazaki M, et al. The application of a three-step proteome analysis for identification of new biomarkers of pancreatic cancer. Int J Proteomics. 2011;2011:628787.
pubmed: 22091389
pmcid: 3199071
doi: 10.1155/2011/628787
Chang SC, Lin WL, Chang YF, Lee CT, Wu JS, Hsu PH, Chang CF. Glycoproteomic identification of novel plasma biomarkers for oral cancer. J Food Drug Anal. 2019;27(2):483–93.
pubmed: 30987719
pmcid: 9296197
doi: 10.1016/j.jfda.2018.12.008
Farrokhi Yekta R, Arefi Oskouie A, Rezaei Tavirani M, Mohajeri-Tehrani MR, Soroush AR. Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: a proteomic study. Int J Biol Markers. 2018;33(4):455–62.
pubmed: 30058426
doi: 10.1177/1724600818787752
Li D, Wu J, Liu Z, Qiu L, Zhang Y. Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry. PeerJ. 2020;8:e9507.
pubmed: 32704452
pmcid: 7346861
doi: 10.7717/peerj.9507
Eckardt KU, Barthlein B, Baid-Agrawal S, Beck A, Busch M, Eitner F, Ekici AB, Floege J, Gefeller O, Haller H, et al. The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol Dial Transplant. 2012;27:1454–60.
pubmed: 21862458
doi: 10.1093/ndt/gfr456
Titze S, Schmid M, Kottgen A, Busch M, Floege J, Wanner C, Kronenberg F, Eckardt KU. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant. 2015;30:441–51.
pubmed: 25271006
doi: 10.1093/ndt/gfu294
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van LF, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
pubmed: 19414839
pmcid: 2763564
doi: 10.7326/0003-4819-150-9-200905050-00006
Kronenberg F, Lobentanz E-M, König P, Utermann G, Dieplinger H. Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol and triglycerides. J Lipid Res. 1994;35:1318–28.
pubmed: 7964193
doi: 10.1016/S0022-2275(20)39975-2
Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110–20.
pubmed: 7579063
doi: 10.1681/ASN.V61110
Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE. C-reactive protein and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst. 2010;102(3):202–6.
pubmed: 20056955
doi: 10.1093/jnci/djp459
Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis. 2014;63(5):820–34.
pubmed: 24485147
pmcid: 4001724
doi: 10.1053/j.ajkd.2013.12.006
Porta C, Bamias A, Danesh FR, Debska-Slizien A, Gallieni M, Gertz MA, Kielstein JT, Tesarova P, Wong G, Cheung M, et al. KDIGO controversies conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney Int. 2020;98(5):1108–19.
pubmed: 33126977
doi: 10.1016/j.kint.2020.06.046
Lees JS, Elyan BMP, Herrmann SM, Lang NN, Jones RJ, Mark PB. The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes. Nephrol Dial Transplant. 2023;38(5):1071–9.
pubmed: 35090037
doi: 10.1093/ndt/gfac011
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Lazebnik Y. What are the hallmarks of cancer? Nat Rev Cancer. 2010;10(4):232–3.
pubmed: 20355252
doi: 10.1038/nrc2827
Shearston K, Tan JTM, Cochran BJ, Rye KA. Inhibition of Vascular Inflammation by Apolipoprotein A-IV. Front Cardiovasc Med. 2022;9:901408.
pubmed: 35845068
pmcid: 9279673
doi: 10.3389/fcvm.2022.901408
Ebert T, Neytchev O, Witasp A, Kublickiene K, Stenvinkel P, Shiels PG. Inflammation and oxidative stress in chronic kidney disease and dialysis patients. Antioxid Redox Signal. 2021;35(17):1426–48.
pubmed: 34006115
doi: 10.1089/ars.2020.8184
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.
pubmed: 12490959
pmcid: 2803035
doi: 10.1038/nature01322
Vidal-Vanaclocha F. Inflammation in the molecular pathogenesis of cancer and atherosclerosis. Reumatol Clin. 2009;5(Suppl 1):40–3.
pubmed: 21794641
doi: 10.1016/j.reuma.2008.12.008
Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):50.
pubmed: 30340457
pmcid: 6195709
doi: 10.1186/s12199-018-0740-1
Masoudkabir F, Sarrafzadegan N, Gotay C, Ignaszewski A, Krahn AD, Davis MK, Franco C, Mani A. Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017;263:343–51.
pubmed: 28624099
pmcid: 6207942
doi: 10.1016/j.atherosclerosis.2017.06.001
Volovat SR, Volovat C, Miron I, Kanbay M, Goldsmith D, Lungulescu C, Badarau SC, Covic A. Oncogenic mechanisms in renal insufficiency. Clin Kidney J. 2021;14(2):507–15.
pubmed: 33623673
doi: 10.1093/ckj/sfaa122
Spaulding HL, Saijo F, Turnage RH, Alexander JS, Aw TY, Kalogeris TJ. Apolipoprotein A-IV attenuates oxidant-induced apoptosis in mitotic competant, undifferentiated cells by modulating intracellular glutathione redox balance. Am J Physiol Cell Physiol. 2005;290:C95–103.
pubmed: 16120654
doi: 10.1152/ajpcell.00388.2005
Satoh M. Endothelial dysfunction as an underlying pathophysiological condition of chronic kidney disease. Clin Exp Nephrol. 2012;16(4):518–21.
pubmed: 22669535
doi: 10.1007/s10157-012-0646-y
Malhab LJB, Saber-Ayad MM, Al-Hakm R, Nair VA, Paliogiannis P, Pintus G, Abdel-Rahman WM. Chronic inflammation and cancer: the role of endothelial dysfunction and vascular inflammation. Curr Pharm Des. 2021;27(18):2156–69.
pubmed: 33655853
doi: 10.2174/1381612827666210303143442
Franses JW, Drosu NC, Gibson WJ, Chitalia VC, Edelman ER. Dysfunctional endothelial cells directly stimulate cancer inflammation and metastasis. Int J Cancer. 2013;133(6):1334–44.
pubmed: 23463345
pmcid: 3707950
doi: 10.1002/ijc.28146
Duka A, Fotakis P, Georgiadou D, Kateifides A, Tzavlaki K, von Eckardstein L, Stratikos E, Kardassis D, Zannis VI. ApoA-IV promotes the biogenesis of apoA-IV-containing HDL particles with the participation of ABCA1 and LCAT. J Lipid Res. 2013;54(1):107–15.
pubmed: 23132909
pmcid: 3520517
doi: 10.1194/jlr.M030114
Ganjali S, Ricciuti B, Pirro M, Butler AE, Atkin SL, Banach M, Sahebkar A. High-density lipoprotein components and functionality in cancer: state-of-the-art. Trends Endocrinol Metab. 2019;30(1):12–24.
pubmed: 30473465
doi: 10.1016/j.tem.2018.10.004
Cheung CYS, Parikh J, Farrell A, Lefebvre M, Summa-Sorgini C, Battistella M. Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: a systematic review of thrombosis and bleeding outcomes. Ann Pharmacother. 2021;55(6):711–22.
pubmed: 33073581
doi: 10.1177/1060028020967635
Fernandes CJ, Morinaga LTK, Alves JL Jr, Castro MA, Calderaro D, Jardim CVP, Souza R. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev. 2019;28(151):180119.
pubmed: 30918022
pmcid: 9488553
doi: 10.1183/16000617.0119-2018
Peng H, Pan S, Yan Y, Brand RE, Petersen GM, Chari ST, Lai LA, Eng JK, Brentnall TA, Chen R. Systemic proteome alterations linked to early stage pancreatic cancer in diabetic patients. Cancers (Basel). 2020;12(6):1534.
pubmed: 32545216
pmcid: 7352938
doi: 10.3390/cancers12061534
Nabeta R, Katselis GS, Chumala P, Dickinson R, Fernandez NJ, Meachem MD. Identification of potential plasma protein biomarkers for feline pancreatic carcinoma by liquid chromatography tandem mass spectrometry. Vet Comp Oncol. 2022;20(3):720–31.
pubmed: 35514180
doi: 10.1111/vco.12826
Cohen RD, Castellani LW, Qiao JH, Van Lenten BJ, Lusis AJ, Reue K. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest. 1997;99:1906–16.
pubmed: 9109435
pmcid: 508015
doi: 10.1172/JCI119358
Duverger N, Tremp G, Caillaud JM, Emmanuel F, Castro G, Fruchart JC, Steinmetz A, Denèfle P. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science. 1996;273(5277):966–8.
pubmed: 8688083
doi: 10.1126/science.273.5277.966